Catalyst Wire Dossier Catalyst Wire Dossier

Recombinant birch pollen allergen

· Allergopharma GmbH & Co. KG
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Recombinant birch pollen allergen, covering 2013-03-11 to 2013-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis [Phase 3]

See pricing